

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:  
Ginette Serrero

Application No.: Not Yet Assigned

Group Art Unit: 1642

Filed: April 4, 2001

Examiner: M. Wells

For: 88KDA TUMORIGENIC GROWTH  
FACTOR AND ANTAGONISTS

11046 U.S. PTO  
09/024647  
04/04/01



INFORMATION DISCLOSURE STATEMENT (IDS)

Dear Sir:

Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement accompanies the new patent application submitted herewith.

Those patents or publications which are marked with an asterisk (\*) in the attached form PTO/SB/08 (facsimile) are not supplied because they were previously cited by or submitted to the Office in a prior application no. 09/456,886 filed December 8, 1999, which is a divisional of application 08/991,862, filed December 16, 1997 and relied upon in this application for an earlier filing date under 35 U.S.C. 120.

A concise explanation of relevance of the items listed on form PTO/SB/08 is:

[ x] not given

[ ] given for each listed item

[ ] given for only non-English language listed items


[ ] in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references

While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR 1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Commissioner is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 04-1073, under Order No. A7542.0000/P001-E. A duplicate copy of this paper is enclosed.

Dated: April 4, 2001

Respectfully submitted,  
  
By \_\_\_\_\_  
James W. Brady, Jr.  
Registration No.: 32,115  
Jeremy A. Cubert  
Registration No.: 40,399  
DICKSTEIN SHAPIRO MORIN & OSHINSKY LLP  
2101 L Street NW  
Washington, DC 20037-1526  
(202) 785-9700  
Attorneys for Applicant